, Volume 76, Issue 8, pp 853–867 | Cite as

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

  • Philippe MoreauEmail author
  • Niels W. C. J. van de Donk
  • Jesus San Miguel
  • Henk Lokhorst
  • Hareth Nahi
  • Dina Ben-Yehuda
  • Michele Cavo
  • Gordon Cook
  • Michel Delforge
  • Hermann Einsele
  • Sonja Zweegman
  • Heinz Ludwig
  • Christoph Driessen
  • Antonio Palumbo
  • Thierry Facon
  • Torben Plesner
  • Meletios Dimopoulos
  • Pia Sondergeld
  • Pieter Sonneveld
  • María-Victoria Mateos
Therapy in Practice


Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number of mAbs directed at myeloma cell surface molecules are in development. Daratumumab is a CD38 mAb that has demonstrated substantial activity and good tolerability in four phase I, phase I/II and phase II studies as monotherapy, as well as in combination with current standard treatments in MM. The positive results obtained in the relapsed/refractory setting in patients with advanced-stage disease and in a small number of patients with newly diagnosed disease provide the rationale for the investigation of the agent in a number of ongoing phase III trials. mAbs are generally better tolerated than conventional chemotherapy; however, their use requires other special considerations. Such factors include those common to all mAbs, namely infusion-related reactions, but also factors that are observed with mAbs used in myeloma, such as interference with response assessment, or factors that are related to CD38 mAbs such as daratumumab, for instance blood typing interference. Our review provides an overview of the results from the daratumumab clinical trials conducted to date, as well as practical management considerations for the use of daratumumab based on our experience with the agent.


Multiple Myeloma Bortezomib Lenalidomide Overall Response Rate Chimeric Antigen Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Medical writing and editorial support was provided by Pia Sondergeld (University of Giessen, Germany) and was funded by Janssen.

Conflicts of interest

Philippe Moreau received fees for advisory board participation from Janssen, Celgene, Bristol–Myers Squibb, Novartis, Takeda, and Amgen. Niels W. C. J. van de Donk received a research Grant from Celgene, Janssen Pharmaceuticals, and Amgen. Jesus San Miguel received fees for advisory board participation from Millennium, Celgene, Novartis, Onyx, Janssen, Bristol–Myers Squibb, and Merck Sharp and Dohme. Henk Lokhorst received fees for attending advisory boards on daratumumab (Janssen). Michele Cavo received honoraria from Janssen, Cilag, Takeda, and Bristol–Myers Squibb, and payment for lectures from Janssen, Cilag, and Takeda. Gordon Cook received Grants from Janssen, Celgene, Takeda, and Chugai-Pharmaceutical Co.; consulting fees or honorarium from Janssen, Celgene, Takeda, Sanofi, Bristol–Myers Squibb, Glycomimetics, and Amgen; support for travel from Janssen, Celgene, Takeda, Sanofi; fees for participation in review activities from Celgene, and Glycomimetics; and payment for lectures from Janssen, Celgene, Takeda, Sanofi, Bristol–Myers Squibb, and Amgen. Michel Delforge received a Grant from Celgene (phase IV clinical trial), and honoraria from Amgen, Celgene, Janssen, Novartis, and Takeda. Hermann Einsele received consulting fees or honorarium, payment for lectures, and support for travel from Janssen, Celgene, Amgen, and Novartis. Sonja Zweegman received honoraria for advisory board participation from Celgene, Takeda, Janssen, and Novartis (honorarium for departmental use, not personal use), and lectures for Celgene and Janssen (payment for departmental use only). Heinz Ludwig received fees for participation in data monitoring committees of early daratumumab studies. Christoph Driessen received consulting honorarium related to daratumumab from Janssen–Cilag (not related to the current manuscript). Antonio Palumbo received consulting fees and honoraria from Janssen–Cilag (not related to the current manuscript). Thierry Facon received fees for advisory board participation, as well as support for travel and payment for lectures from Janssen. He undertakes advisory board activities with Janssen and is on the speaker’s bureau for Janssen. Torben Plesner received a research Grant from Janssen, honoraria for advisory board participation from Genmab and Janssen, and payment for lectures from Janssen. Meletios Dimopoulos has received consulting fees or honoraria from Janssen, Celgene, Novartis, and Amgen. Pia Sondergeld received payment from Janssen for the writing of this manuscript. Pieter Sonneveld received Grants from Amgen, Celgene, Janssen, and Karyopharm; consulting fees or honoraria from Amgen, Celgene, Janssen, and Karyopharm; fees for participation in review activities from Celgene and Janssen; provision of writing assistance from Janssen; and payment for lectures from Amgen, Celgene, and Janssen. He has been involved in drug research, i.e. clinical trials, both investigator-initiated and company-initiated, and has served on advisory boards and given lectures in the context of new drug development for multiple myeloma. Maria-Victoria Mateos has received honoraria for lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, and Bristol–Myers Squibb. Hareth Nahi and Dina Ben-Yehuda have no conflicts of interest to declare.


  1. 1.
    Grillo-López AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90(11):981–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26:149–57.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014;23(4):445–52.CrossRefPubMedGoogle Scholar
  6. 6.
    US FDA. FDA approves Darzalex for patients with previously treated multiple myeloma. Accessed 25 Mar 2016.
  7. 7.
    The Myeloma Beacon™. Janssen submits marketing authorisation application for daratumumab for European patients with heavily pre-treated multiple myeloma. Accessed 25 Mar 2016.
  8. 8.
    Mehta K, Shahid U, Malavasi F. HumanCD38, a cell-surface protein with multiple functions. FASEB J. 1996;10(12):1408–17.PubMedGoogle Scholar
  9. 9.
    Funaro A, Malavasi F. Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. J Biol Regul Homeost Agents. 1999;13(1):54–61.PubMedGoogle Scholar
  10. 10.
    Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841–86.CrossRefPubMedGoogle Scholar
  11. 11.
    Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci. 2015;1335:10–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood. 2006;108(4):1135–44.CrossRefPubMedGoogle Scholar
  14. 14.
    Partida-Sánchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med. 2001;7(11):1209–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Partida-Sánchez S, Randall TD, Lund FE. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclaseactivity. Microbes Infect. 2003;5(1):49–58.CrossRefPubMedGoogle Scholar
  16. 16.
    Fedele G, Di Girolamo M, Recine U, Palazzo R, Urbani F, Horenstein AL, et al. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation. Mediat Inflamm. 2013;2013:564687.CrossRefGoogle Scholar
  17. 17.
    Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34 + CD38-progenitor cells. Blood. 1991;77(6):1218–27.PubMedGoogle Scholar
  18. 18.
    Theilgaard-Mönch K, Raaschou-Jensen K, Schjødt K, Heilmann C, Vindeløv L, Jacobsen N, et al. Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts. Bone Marrow Transpl. 2003;32(12):1125–33.CrossRefGoogle Scholar
  19. 19.
    Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, Di Raimondo F, et al. Flow cytometric detection of aneuploidCD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28(5):469–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med. 2013;19:99–108.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Overdijk MB, Verploegen S, Bögels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiplemyeloma. MAbs. 2015;7(2):311–21.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jansen JH, Boross P, Overdijk MB, van Bueren JJ, Parren PW, Leusen JH. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking [abstract no. 2974]. American Society of Hematology Proceedings 2012. Blood. 2012;120(21):2974.Google Scholar
  25. 25.
    Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract no. 3474]. Blood. 2014;124(21):3474.Google Scholar
  26. 26.
    Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6(3):120–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Krejcik J, Casneuf T, Nijhof I, Verbist B, Bald J, Plesner T, et al. Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma [abstract no. 3037]. In: American society of hematology 57th annual meeting and exposition, 5–8 Dec 2015, Orlando (FL).Google Scholar
  28. 28.
    van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284–90.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar RA, Bakker JM, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802–10.CrossRefPubMedGoogle Scholar
  31. 31.
    Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.CrossRefPubMedGoogle Scholar
  32. 32.
    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. Epub. 2016. doi: 10.1016/S0140-6736(15)01120-4.Google Scholar
  33. 33.
    Usmani S, Weiss B, Bahlis NJ, Belch A, Lonial S, Lokhorst H, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma [abstract no. 29]. In: American Society of Hematology 57th Annual Meeting and Exposition, 5–8 Dec 2015, Orlando (FL).Google Scholar
  34. 34.
    Usmani S, Ahmadi T, Ng Y, Lam A, Potluri R, Mehra M. Analyses of real world data on overall survival in multiple myeloma patients with at least 3 prior lines of therapy including a PI and an IMiD, or double refractory to a PI and an IMiD [abstract no. 4498]. In: American Society of Hematology 57th Annual Meeting and Exposition, 5–8 Dec 2015, Orlando (FL).Google Scholar
  35. 35.
    Plesner T, Arkenau HT, Lokhorst HM, Gimsing P, Krejcik J, Lemech C, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma [abstract no. 84]. Blood. 2014;124(21):84.Google Scholar
  36. 36.
    Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503) [abstract no. 507]. Blood. 2015;126(23):507.Google Scholar
  37. 37.
    Mateos MV, Moreau P, Comenzo R, Bladé J, Benboubker L, de la Rubia J, et al. An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma [abstract no. P275]. In: European Hematology Association 20th Congress, 11–14 Jun 2015, Vienna.Google Scholar
  38. 38.
    Moreau P, Mateos MV, Bladé J, et al. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma [abstract no. 176]. In: American Society of Hematology 56th Annual Meeting and Exposition, 6–9 Dec 2014, San Francisco (CA).Google Scholar
  39. 39.
    Chari A, Lonial S, Suvannasankha A, Fay JW, Arnulf B, Ifthikharuddin JJ, et al. Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract no. 508]. In: American Society of Hematology 57th Annual Meeting and Exposition, 5–8 Dec 2015, Orlando (FL).Google Scholar
  40. 40.
    Darzalex™ (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL. Accessed 25 Mar 2016.
  41. 41.
    Kroll MH, Elin RJ. Interference with clinical laboratory analyses. Clin Chem. 1994;40(11 Pt 1):1996–2005.PubMedGoogle Scholar
  42. 42.
    King RI, Florkowski CM. How paraproteins can affect laboratory assays: spurious results and biological effects. Pathology. 2010;42(5):397–401.CrossRefPubMedGoogle Scholar
  43. 43.
    Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PW, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–62.CrossRefPubMedGoogle Scholar
  44. 44.
    Ostrov BE, Amsterdam D. The interference of monoclonal antibodies with laboratory diagnosis: clinical and diagnostic implications. Immunol Invest. 2013;42(8):673–90.CrossRefPubMedGoogle Scholar
  45. 45.
    Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–54.CrossRefPubMedGoogle Scholar
  46. 46.
    Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, et al. A single protein immunologically identified as CD38 displays NAD1 glycohydrolase, ADP-ribosylcyclase and cyclic ADP-ribosehydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196:1459–65.CrossRefPubMedGoogle Scholar
  47. 47.
    Albeniz I, Demir O, Türker-Sener L, Yalçintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. Hematology. 2007;12(5):409–14.CrossRefPubMedGoogle Scholar
  48. 48.
    Chari A, Satta T, Tayal A, Jagannath S, Cho HJ, Parekh S, et al. Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab [abstract no. 3571]. In: American Society of Hematology 57th Annual Meeting and Exposition, 5–8 Dec 2015, Orlando (FL).Google Scholar
  49. 49.
    Bossuyt X. Interferences in clinical capillary zone electrophoresis of serum proteins. Electrophoresis. 2004;25:1485–7.CrossRefPubMedGoogle Scholar
  50. 50.
    McCudden CR, Voorhees PM, Hainsworth SA, Whinna HC, Chapman JF, Hammett-Stabler CA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem. 2010;56(12):1897–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol. 2011;155(1):123–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Axel AE. McCudden CR, Xie H, Hall BM, Sasser AK. Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma [abstract no. 2563]. In: Proceedings of the American Association for Cancer Research (AACR) Annual Meeting 2014, 5–9 April 2014, San Diego (CA).Google Scholar
  53. 53.
    Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.CrossRefPubMedGoogle Scholar
  54. 54.
    McCudden C, Axel A, Slaets D, Frans S, Bald J, Schecter JM, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody [abstract no. 8590]. J Clin Oncol. 2015;33:8590.Google Scholar
  55. 55.
    Durie BGM, San Miguel JF, Blade J, Rajkumar SV, on behalf of the International Myeloma Working Group. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29(12):2416–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001;24:767–79.CrossRefPubMedGoogle Scholar
  57. 57.
    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Cornwell GG 3rd, Pajak TF, McIntyre OR. Hypersensitivity reactions to ivmelphalan during treatment of multiple myeloma: cancer and Leukemia Group B experience. Cancer Treat Rep. 1979;63(3):399–403.PubMedGoogle Scholar
  59. 59.
    Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14(9):1430–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–32.CrossRefPubMedGoogle Scholar
  61. 61.
    Siegel DS. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013;4(6):354–65.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Meisel K, Rizvi S. Complications of monoclonal antibody therapy. Med Health R I. 2011;94(11):317–9.PubMedGoogle Scholar
  64. 64.
    Voorhees P, Weiss B, Usmani S, Huaibao F, Uhlar CM, Khan I, et al. Management of infusion-related reactions following daratumumab monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (SIRIUS) [abstract no. 1829]. Blood. 2015;126(23):1829Google Scholar
  65. 65.
    Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–13.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Alici E, Chrobok M, Lund J, Ahmadi T, Khan I, Duru AD, et al. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol. Epub. 2015. doi: 10.1111/bjh.13776.Google Scholar
  67. 67., a service of the US National Institutes of Health. Accessed 25 Mar 2016.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Philippe Moreau
    • 1
    Email author
  • Niels W. C. J. van de Donk
    • 2
  • Jesus San Miguel
    • 3
  • Henk Lokhorst
    • 2
  • Hareth Nahi
    • 4
  • Dina Ben-Yehuda
    • 5
  • Michele Cavo
    • 6
  • Gordon Cook
    • 7
  • Michel Delforge
    • 8
  • Hermann Einsele
    • 9
  • Sonja Zweegman
    • 2
  • Heinz Ludwig
    • 10
  • Christoph Driessen
    • 11
  • Antonio Palumbo
    • 12
  • Thierry Facon
    • 13
  • Torben Plesner
    • 14
  • Meletios Dimopoulos
    • 15
  • Pia Sondergeld
    • 16
  • Pieter Sonneveld
    • 17
  • María-Victoria Mateos
    • 18
  1. 1.Hematology DepartmentUniversity Hospital Hôtel-DieuNantesFrance
  2. 2.VU University Medical CenterAmsterdamThe Netherlands
  3. 3.University Hospital NavarraPamplonaSpain
  4. 4.Karolinska University Hospital HuddingeStockholmSweden
  5. 5.Hadassah Medical CenterJerusalemIsrael
  6. 6.University School of MedicineBolognaItaly
  7. 7.St James’s University HospitalLeedsUK
  8. 8.Catholic University of LeuvenLeuvenBelgium
  9. 9.Julius Maximilian UniversityWürzburgGermany
  10. 10.Wilhelminen hospitalViennaAustria
  11. 11.Kantonsspital St. GallenSt. GallenSwitzerland
  12. 12.University of TorinoTorinoItaly
  13. 13.University Hospital LilleLilleFrance
  14. 14.Vejle Hospital and University of Southern DenmarkVejleDenmark
  15. 15.University Athens School of MedicineAthensGreece
  16. 16.University of GiessenGiessenGermany
  17. 17.Erasmus MC Cancer InsituteRotterdamThe Netherlands
  18. 18.University Hospital of SalamancaSalamancaSpain

Personalised recommendations